How is sermorelin dosed and mixed?
Draw to
unitsmL
0.3 mL · 30 units syringe0.5 mL · 50 units syringe1 mL · 100 units syringe3 mL · 3cc syringe0.5 mL · 20 units, U-40 syringe1 mL · 40 units, U-40 syringe
Concentration is the powder in the vial divided by the water. The draw is the dose divided by the concentration, in mL, times 100 on a U-100 syringe or 40 on a U-40. Every figure comes from what you enter.
Save to Milligram
Open in Milligram shows once the calculator has a result.
Open in Milligram is off while the dose is more than the whole vial. Check the dose and its unit.
Open in Milligram is off while the draw is under one unit. Check the dose and its unit.
Open in Milligram adds Sermorelin and this dose to a plan in the app, with the schedule you pick here. The vial and water are not saved.
A secondary prescribing text on RxList gives 0.2 - 0.3 mg of sermorelin acetate once daily at bedtime by subcutaneous injection, and a second passage prints the unit as mcg.1
Every vial at a glance. Pick a cell to draw it on the syringe.
| Vial | 1 mL of water | 2 mL of water |
|---|---|---|
| 0.5 mg | 0.5 mg/mL: 200 mcg is 40 units, 300 mcg is 60 units | 0.25 mg/mL: 200 mcg is 80 units, 300 mcg is over 1 mL |
| 1 mg | 1 mg/mL: 200 mcg is 20 units, 300 mcg is 30 units | 0.5 mg/mL: 200 mcg is 40 units, 300 mcg is 60 units |
Vial strengths and syringe arithmetic
An FDA notice lists Geref (sermorelin acetate) injection at 0.5 mg and 1.0 mg per vial, an approval FDA withdrew effective June 18, 2009, and the table works those two strengths.2 A secondary prescribing text on RxList lists a 0.5 mg vial and a 3.0 mg vial instead, each packed with a 2 mL vial of Sodium Chloride Injection, USP.1 It says to reconstitute with that diluent, aiming it at the vial wall and swirling gently until dissolved.1 It does not say how much diluent to add, so each water volume in the table is arithmetic only.1 The table's 200 and 300 mcg take that text's 0.2 - 0.3 mg passage, but its other passage gives 0.2 - 0.3 mcg, so the text settles no dose and no mark in the table is a label figure.1 More on mixing a vial is in the mixing guide.
The sermorelin calculator works the 0.5 mg and 1.0 mg vials at any diluent volume.2
Sermorelin dose and schedule
The RxList text does not settle the unit: one passage gives 0.2 - 0.3 mg once daily at bedtime and another 0.2 - 0.3 mcg.1 The adult trials in the evidence used GHRH or an analogue, not a product labelled sermorelin.
| Trial | Dose and schedule | People | Length |
|---|---|---|---|
| Thorner 1996 (Geref International Study Group), open label | 30 micrograms/kg GHRH-(1-29) once daily sc at bedtime3 | 110 previously untreated prepubertal GH-deficient children, eighty-six analysed for efficacy | up to 1 yr |
| Kirk 1994 | GHRHa 20 micrograms/kg by twice daily subcutaneous injection4 | Eighteen short pre-pubertal children aged 4.3-11.0 years with idiopathic short stature, one withdrawn before 3 months | one year |
| Corpas 1992, randomized order | Low (0.5 mg) and high (1 mg) dose GHRH-(1-29) sc injections twice daily5 | 10 healthy nonobese old men (68.0 +/- 6.2 yr), compared at baseline with 9 young men | 14 days each, with a 14-day nontreatment period between |
| Vittone 1997 | 2 mg GHRH every night by subcutaneous self-injection6 | Eleven healthy, non-obese men aged 64 to 76 with low baseline IGF-I | 6 weeks |
| Khorram 1997, single blind, randomized, placebo-controlled (analogue, not sermorelin) | 10 microg/kg [Nle27]GHRH-(1-29)-NH2 sc every night, after 4 weeks of nightly placebo7 | Ten women and nine men aged 55 to 71 | 16 weeks of analogue, 5 months in all |
In the Corpas trial, GH and IGF-I rose with dose, and mean 24-hour GH and IGF-I differed significantly from the old men's basal values only at the high dose.5 The Vittone authors wrote that their data suggest single nightly doses of GHRH are less effective than multiple daily doses in eliciting GH- and/or IGF-I-mediated effects; IGF-I did not change in their eleven men.6
Storing sermorelin
The RxList text says unmixed vials are stored refrigerated at 2-8 C (36-46 F).1 The Irish Summary of Product Characteristics for Geref 50, an ampoule of 50 micrograms of sermorelin for testing the anterior pituitary by a single intravenous injection, says to store it at 2°C to 8°C and protect it from light, gives a shelf life of 2 years, and says to reconstitute it immediately before use and discard any product remaining after use.8 The evidence gives no storage time for a mixed vial.
Frequently asked questions
Is sermorelin approved?
The RxList text says sermorelin is approved for diagnostic evaluation of pituitary function and for increasing growth in children, that off label usage may include acute or age-related growth hormone insufficiency, and elsewhere that sermorelin acetate is discontinued.1 FDA withdrew approval of both Geref applications (NDA 19-863 and NDA 20-443) effective June 18, 2009, and determined that both Geref products were not withdrawn from sale for reasons of safety or effectiveness.2 The sermorelin compound page has the history. No current US label for sermorelin turned up in the evidence: a DailyMed search for sermorelin returned no labels.
Where is sermorelin injected?
The RxList text says to inject subcutaneously and to rotate injection sites periodically.1
Can you take sermorelin and HGH at the same time?
Nothing in the evidence addresses sermorelin and HGH together. HGH doses in IU are in the HGH dosage guide.
Is there a sermorelin dosage for men?
No label in the evidence gives a sermorelin dose by sex. Khorram 1997, a trial of a GHRH analogue, not sermorelin, in ten women and nine men aged 55 to 71, gave all of them 10 microg/kg and reported increased lean body mass in men only.7
References
- RxList. Sermorelin Acetate (Sermorelin): Side Effects, Uses, Dosage, Interactions, Warnings. rxlist.com
- FDA / Federal Register. Federal Register, Volume 78 Issue 42 (Monday, March 4, 2013). govinfo.gov
- The Journal of clinical endocrinology and metabolism (PubMed abstract). Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group. 1996. pubmed.ncbi.nlm.nih.gov
- Clinical endocrinology (PubMed abstract). Treatment with GHRH(1-29)NH2 in children with idiopathic short stature induces a sustained increase in growth velocity. 1994. pubmed.ncbi.nlm.nih.gov
- The Journal of clinical endocrinology and metabolism (PubMed abstract). Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. 1992. pubmed.ncbi.nlm.nih.gov
- Metabolism: clinical and experimental (PubMed abstract). Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men. 1997. pubmed.ncbi.nlm.nih.gov
- The Journal of clinical endocrinology and metabolism (PubMed abstract). Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. 1997. pubmed.ncbi.nlm.nih.gov
- HPRA. License. assets.hpra.ie